EF
PRAX icon

Empowered Funds’s Praxis Precision Medicines PRAX Stock Holding History

Empowered Funds’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,852
Closed -$10.9M – 2182
2025
Q4 		$10.9M Buy
+36,852
New +$6.86M 0.18% 117

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Empowered Funds's PRAX Position: Q1 2026 in Review

Empowered Funds sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 36,852 shares — an estimated $10.9M sold.

Empowered Funds first reported a position in PRAX in Q4 2025 and held it in 1 quarter. The position peaked at $10.9M in Q4 2025. 291 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Empowered Funds reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
  • Empowered Funds sold 36,852 Praxis Precision Medicines shares in Q1 2026, an estimated $10.9M.
  • Empowered Funds first reported a position in Praxis Precision Medicines in Q4 2025 and held it in 1 quarter.
  • Empowered Funds's Praxis Precision Medicines position peaked at $10.9M in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.